These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

347 related articles for article (PubMed ID: 25411844)

  • 1. Fingolimod increases CD39-expressing regulatory T cells in multiple sclerosis patients.
    Muls N; Dang HA; Sindic CJ; van Pesch V
    PLoS One; 2014; 9(11):e113025. PubMed ID: 25411844
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Regulation of Treg-associated CD39 in multiple sclerosis and effects of corticotherapy during relapse.
    Muls NG; Dang HA; Sindic CJ; van Pesch V
    Mult Scler; 2015 Oct; 21(12):1533-45. PubMed ID: 25662347
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Peripheral CD39-expressing T regulatory cells are increased and associated with relapsing-remitting multiple sclerosis in relapsing patients.
    Álvarez-Sánchez N; Cruz-Chamorro I; Díaz-Sánchez M; Lardone PJ; Guerrero JM; Carrillo-Vico A
    Sci Rep; 2019 Feb; 9(1):2302. PubMed ID: 30783191
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Peripheral blood T cell dynamics predict relapse in multiple sclerosis patients on fingolimod.
    Song ZY; Yamasaki R; Kawano Y; Sato S; Masaki K; Yoshimura S; Matsuse D; Murai H; Matsushita T; Kira J
    PLoS One; 2014; 10(4):e0124923. PubMed ID: 25919001
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CD39+ regulatory T cells attenuate allergic airway inflammation.
    Li P; Gao Y; Cao J; Wang W; Chen Y; Zhang G; Robson SC; Wu Y; Yang J
    Clin Exp Allergy; 2015 Jun; 45(6):1126-37. PubMed ID: 25728362
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CD39+Foxp3+ regulatory T Cells suppress pathogenic Th17 cells and are impaired in multiple sclerosis.
    Fletcher JM; Lonergan R; Costelloe L; Kinsella K; Moran B; O'Farrelly C; Tubridy N; Mills KH
    J Immunol; 2009 Dec; 183(11):7602-10. PubMed ID: 19917691
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CD39/CD73 and the imbalance of Th17 cells and regulatory T cells in allergic asthma.
    Wang LL; Tang HP; Shi GC; Wan HY; Tang W; Hou XX; Pan LN; Shi BY; Tao LQ
    Mol Med Rep; 2013 Nov; 8(5):1432-8. PubMed ID: 24065069
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fingolimod does not impair T-cell release from the thymus and beneficially affects Treg function in patients with multiple sclerosis.
    Haas J; Schwarz A; Korporal-Kunke M; Jarius S; Wiendl H; Kieseier BC; Wildemann B
    Mult Scler; 2015 Oct; 21(12):1521-32. PubMed ID: 25583847
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of fingolimod on CD4+ T cell subset and cytokine profile of relapsing remitting multiple sclerosis patients.
    Kürtüncü M; Yılmaz V; Akçay Hİ; Türkoğlu R; Altunrende B; Çınar SA; Ulusoy C; Gündüz T; İçöz S; Kasap M; Çalışkan Z; Ötünç G; Eraksoy M; Tüzün E
    J Neuroimmunol; 2019 Dec; 337():577065. PubMed ID: 31526917
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CD39 expression on Treg and Th17 cells is associated with metabolic factors in patients with type 2 diabetes.
    Cortez-Espinosa N; Cortés-Garcia JD; Martínez-Leija E; Rodríguez-Rivera JG; Barajas-López C; González-Amaro R; Portales-Pérez DP
    Hum Immunol; 2015 Sep; 76(9):622-30. PubMed ID: 26386144
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fingolimod therapy modulates circulating B cell composition, increases B regulatory subsets and production of IL-10 and TGFβ in patients with Multiple Sclerosis.
    Blumenfeld S; Staun-Ram E; Miller A
    J Autoimmun; 2016 Jun; 70():40-51. PubMed ID: 27055778
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Expression of ectonucleotidase CD39 by Foxp3+ Treg cells: hydrolysis of extracellular ATP and immune suppression.
    Borsellino G; Kleinewietfeld M; Di Mitri D; Sternjak A; Diamantini A; Giometto R; Höpner S; Centonze D; Bernardi G; Dell'Acqua ML; Rossini PM; Battistini L; Rötzschke O; Falk K
    Blood; 2007 Aug; 110(4):1225-32. PubMed ID: 17449799
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Increased CD39 expression on CD4(+) T lymphocytes has clinical and prognostic significance in chronic lymphocytic leukemia.
    Perry C; Hazan-Halevy I; Kay S; Cipok M; Grisaru D; Deutsch V; Polliack A; Naparstek E; Herishanu Y
    Ann Hematol; 2012 Aug; 91(8):1271-9. PubMed ID: 22349724
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reduced Numbers and Impaired Function of Regulatory T Cells in Peripheral Blood of Ischemic Stroke Patients.
    Ruhnau J; Schulze J; von Sarnowski B; Heinrich M; Langner S; Pötschke C; Wilden A; Kessler C; Bröker BM; Vogelgesang A; Dressel A
    Mediators Inflamm; 2016; 2016():2974605. PubMed ID: 27073295
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification of a novel mechanism of action of fingolimod (FTY720) on human effector T cell function through TCF-1 upregulation.
    Mazzola MA; Raheja R; Murugaiyan G; Rajabi H; Kumar D; Pertel T; Regev K; Griffin R; Aly L; Kivisakk P; Nejad P; Patel B; Gwanyalla N; Hei H; Glanz B; Chitnis T; Weiner HL; Gandhi R
    J Neuroinflammation; 2015 Dec; 12():245. PubMed ID: 26714756
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fingolimod alters the transcriptome profile of circulating CD4+ cells in multiple sclerosis.
    Friess J; Hecker M; Roch L; Koczan D; Fitzner B; Angerer IC; Schröder I; Flechtner K; Thiesen HJ; Winkelmann A; Zettl UK
    Sci Rep; 2017 Feb; 7():42087. PubMed ID: 28155899
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Altered aryl-hydrocarbon-receptor signalling affects regulatory and effector cell immunity in autoimmune hepatitis.
    Vuerich M; Harshe R; Frank LA; Mukherjee S; Gromova B; Csizmadia E; Nasser IAM; Ma Y; Bonder A; Patwardhan V; Robson SC; Longhi MS
    J Hepatol; 2021 Jan; 74(1):48-57. PubMed ID: 32663496
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Isolated CD39 expression on CD4+ T cells denotes both regulatory and memory populations.
    Zhou Q; Yan J; Putheti P; Wu Y; Sun X; Toxavidis V; Tigges J; Kassam N; Enjyoji K; Robson SC; Strom TB; Gao W
    Am J Transplant; 2009 Oct; 9(10):2303-11. PubMed ID: 19656134
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Increased Percentage of CD8
    Houston TW; Howlett-Prieto Q; Regenauer C; Testai FD; Yao F; Feng X; Reder AT
    Neurol Neuroimmunol Neuroinflamm; 2023 Mar; 10(2):. PubMed ID: 36535763
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Alteration of CD39+Foxp3+ CD4 T cell and cytokine levels in EAE/MS following anti-CD52 treatment.
    Pant AB; Wang Y; Mielcarz DW; Kasper EJ; Telesford KM; Mishra M; Haque A; Channon JY; Kasper LH; Begum-Haque S
    J Neuroimmunol; 2017 Feb; 303():22-30. PubMed ID: 28087077
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.